Reclassification on repeat testing
| Second | First | ||||
| <15, stage 5 | 15–29, stage 4 | 30–59, stage 3 | 60–89, stage 2 | >90, stage 1/0 | |
| A. MDRD testing | |||||
| <15, stage 5 | 0.16 | 0.03 | |||
| 15–29, stage 4 | 0.03 | 0.81 | 0.22 | ||
| 30–59, stage 3 | 0.22 | 12.1 | 2.2 | ||
| 60–89, stage 2 | 2.2 | 46.1 | 5.0 | ||
| ≥90, stage 1/0 | 5.0 | 25.8 | |||
| B. CKD-EPI testing | |||||
| <15, stage 5 | 0.19 | 0.04 | |||
| 15–29, stage 4 | 0.04 | 0.94 | 0.25 | ||
| 30–59, stage 3 | 0.25 | 11.1 | 1.8 | ||
| 60–89, stage 2 | 1.8 | 37.8 | 4.2 | ||
| ≥90, stage 1/0 | 4.2 | 37.4 | |||
Values indicate the percentage of all patients tested. Rows and columns refer to eGFR (ml/min/1.73m2) and CKD stage. Each column shows the distribution of people who were originally in that eGFR category group and the rows in the column indicate their subsequent reclassification on repeat measurement of creatinine using the same formula (MDRD in A or CKD-EPI in B). Figures in bold indicate the percentage who do not change classification with repeat testing. Both CKD stages 1 and 2 require a structural or other abnormality in addition to the eGFR criteria.
CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease-Epidemiology Collaboration; GFR, estimated glomerular filtration rate; MDRD, Modification of Diet in Renal Disease.